NAS:ILMN (USA)
Business Description
Illumina Inc
NAICS : 621511
SIC : 8071
5200 Illumina Way, San Diego, CA, USA, 92122
Compare
Compare
Traded in other countries / regions
ILMN.Austria
•
I1LM34.Brazil
•
ILU.Germany
•
ILMN.Mexico
•
0J8Z.UK
•
ILMN.USA
Description
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.51 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | 6.69 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.92 | |||||
Beneish M-Score | -1.61 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.2 | |||||
3-Year EBITDA Growth Rate | 1.5 | |||||
3-Year EPS without NRI Growth Rate | -3.2 | |||||
3-Year FCF Growth Rate | -26.7 | |||||
3-Year Book Growth Rate | 38.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Industry Rank | 18.02 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | 15.08 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.85 | |||||
9-Day RSI | 47.49 | |||||
14-Day RSI | 49.81 | |||||
6-1 Month Momentum % | -40.47 | |||||
12-1 Month Momentum % | -63.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.46 | |||||
Days Inventory | 105.21 | |||||
Days Sales Outstanding | 47.42 | |||||
Days Payable | 64.85 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 67.54 | |||||
Operating Margin % | -6.18 | |||||
Net Margin % | -0.43 | |||||
ROE % | -0.21 | |||||
ROA % | -0.14 | |||||
ROIC % | 5.51 | |||||
ROC (Joel Greenblatt) % | 2.48 | |||||
ROCE % | 0.38 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 62.54 | |||||
Shiller PE Ratio | 52.98 | |||||
Price-to-Owner-Earnings | 131.48 | |||||
PS Ratio | 7.11 | |||||
PB Ratio | 3.18 | |||||
Price-to-Tangible-Book | 394.48 | |||||
Price-to-Free-Cash-Flow | 777.46 | |||||
Price-to-Operating-Cash-Flow | 112.35 | |||||
EV-to-EBIT | 724.29 | |||||
EV-to-Forward-EBIT | 65.5 | |||||
EV-to-EBITDA | 89.84 | |||||
EV-to-Forward-EBITDA | 72.68 | |||||
EV-to-Revenue | 7.42 | |||||
EV-to-Forward-Revenue | 7.53 | |||||
EV-to-FCF | 676.27 | |||||
Price-to-Projected-FCF | 2.09 | |||||
Price-to-DCF (FCF Based) | 40.81 | |||||
Price-to-Median-PS-Value | 0.55 | |||||
Earnings Yield (Greenblatt) % | 0.13 | |||||
Forward Rate of Return (Yacktman) % | -2.57 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:ILMN
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 4,692 | ||
EPS (TTM) ($) | -0.06 | ||
Beta | 1.15 | ||
Volatility % | 40.65 | ||
14-Day RSI | 49.81 | ||
14-Day ATR ($) | 11.178626 | ||
20-Day SMA ($) | 215.61375 | ||
12-1 Month Momentum % | -63.81 | ||
52-Week Range ($) | 173.45 - 524.99 | ||
Shares Outstanding (Mil) | 157.3 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Illumina Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |